Niowave

Explore the latest insights on Niowave and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Niowave’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Harbour BioMed's Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis
CompanyDrug

Harbour BioMed’s Batoclimab Wins NMPA Marketing Approval in China – First‑Class FcRn Antibody Now Indicated for AChR‑Positive Generalized Myasthenia Gravis

Harbour BioMed (HKG: 2142) announced that China's National Medical Products Administration (NMPA) has approved batoclimab for marketing, indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who…

Merck's Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor

Merck’s Welireg (belzutifan) Wins NMPA Approval in China for Pheochromocytoma and Paraganglioma – Second Chinese Indication for the First‑in‑Class HIF‑2α Inhibitor

Novo Nordisk Secures NMPA Indication Update for Wegovy (semaglutide) in China – Expanded Label Now Covers Chinese BMI Criteria for Overweight and Obesity

Novo Nordisk Secures NMPA Indication Update for Wegovy (semaglutide) in China – Expanded Label Now Covers Chinese BMI Criteria for Overweight and Obesity

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion